Connexa Sports Technologies Introduces $300M Mixed Equity Shelf
Source link
Morgan Stanley boosts Gilead’s HIV treatment growth By Investing.com
Investing.com — Upgraded by Morgan Stanley Gilead Sciences Inc (NASDAQ: ) to “overweight” from “equal weight,” raising its price target to $113 from $87 on the HIV prevention drug Lenacapavir…